NewsSource: EClinCloud

EClinCloud Named to "2023 Top 10 Digital Pharmaceutical Companies in China" List

2 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.

Article image

On December 15–16, the [Jingxi Health Talks] CHS 2023 8th China Healthcare Industry Upgrade Summit was held in Beijing, guided by the China Association for the Promotion of Industrial Development and hosted by EqualOcean Healthcare.


Previously, EqualOcean Healthcare released the "CHS 2023 China Healthcare Industry List" series online, and on December 15 presented all lists again in person at the summit alongside an on-site awards ceremony.


EClinCloud was named to the "2023 Top 10 Digital Pharmaceutical Companies in China" list, part of the "CHS 2023 China Digital Healthcare Industry Vitality List" series.

Article image


Article image


As one of the most closely watched annual honors in China's healthcare sector, the "CHS 2023 China Digital Healthcare Industry Vitality List" initiated by EqualOcean Healthcare aims to select, through a multi-tiered, multi-dimensional, and specialized evaluation, those companies with vitality and innovative DNA, investors, and innovative figures with strong leadership in China's healthcare industry, identifying the core drivers of healthcare innovation.


Today, technological innovation is transforming how we live, and the wave of digitalization is sweeping the globe as industries accelerate their digital transformation. In the pharmaceutical sector, digital technology is likewise profoundly transforming traditional clinical R&D; only by grounding development in practice and adapting to changing times can organizations achieve breakthroughs on the path of continuous evolution.


As a provider of digital solutions for clinical research, EClinCloud is dedicated to advancing clinical research through technological innovation to bring effective treatments to patients. EClinCloud's inclusion on the "2023 Top 10 Digital Pharmaceutical Companies in China" list reflects the industry's recognition and affirmation of EClinCloud's products and services.


Looking ahead, EClinCloud will stay true to its founding mission, continue deepening its focus on digital solutions for clinical trials, increase investment in technological innovation, and empower clinical research through digital and intelligent technologies to improve clinical research efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




About EClinCloud

EClinCloud is a technology company dedicated to clinical R&D, offering an integrated, interoperable all-in-one clinical trial cloud platform (including solutions across technology products and solutions such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, including scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (such as the central nervous system and ophthalmology). By combining cutting-edge technology with life sciences data to build a globally leading, patient-centric clinical evidence support SaaS cloud platform, EClinCloud helps domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.






Article image

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.